



Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference

February 19, 2026

IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at TD Cowen's 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 am Eastern Time (7:30 am Pacific Time).

A live audio webcast of the presentation will be available on the Company's website in the "Investors—Events & Presentations" section at <https://investors.betabionics.com>, and will be archived there for future replay following the event.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.

Investor Relations:

Blake Beber
Head of Investor Relations
ir@betabionics.com

Media and Public Relations:

Karen Hynes
Vice President of Marketing
media@betabionics.com

Source: Beta Bionics, Inc.